Mai CW

ORCID: 0000-0001-6532-184X · 1 paper in corpus

2013

Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers.

OncoTargets and therapy ·doi:10.2147/ott.s50838

Toll-like receptor 4 (TLR-4) is well known for its host innate immunity. Despite the fact that TLR-4 activation confers antitumor responses; emerging evidence suggests that TLR-4 is associated with tumor development and progression. It is n…